主页 > 医学信息 >
【文摘发布】肿瘤血管破坏药物在临床上的进展
Vascular disrupting agents in clinical development.
By Hinnen P, Eskens FA.
1Department of Medical Oncology, Erasmus University Medical Center, PO Box 2040, Rotterdam 3000 CA, The Netherlands.
Growth of human tumours depends on the supply of oxygen and nutrients via the surrounding vasculature. Therefore tumour vasculature is an attractive target for anticancer therapy. Apart from angiogenesis inhibitors that compromise the formation of new blood vessels, a second class of specific anticancer drugs has been developed. These so-called vascular disrupting agents (VDAs) target the established tumour vasculature and cause an acute and pronounced shutdown of blood vessels resulting in an almost complete stop of blood flow, ultimately leading to selective tumour necrosis. As a number of VDAs are now being tested in clinical studies, we will discuss their mechanism of action and the results obtained in preclinical studies. Also data from clinical studies will be reviewed and some considerations with regard to the future development are given.British Journal of Cancer (2007) 96, 1159-1165. doi:10.1038/sj.bjc.6603694 www.bjcancer.com Published online 20 March 2007.
PMID: 17375046 [PubMed - in process]
人肿瘤的生长依靠其间的血管系统提供的氧和营养。因此肿瘤血管自然成了抗肿瘤治疗的诱人靶点。除了破坏新生血管形成的血管生成抑制因子，第二代特异抗肿瘤药物已经被开发出来。这些称为血管破坏剂（VDAs）的药物瞄准稳定生长肿瘤的血管系统，快速有效地关闭血管，几乎导致血流完全中断，最后选择性的使肿瘤坏死。目前已有一些VDAs在做临床试验，我们将讨论其作用机制，以及临床前研究的结果。还回顾了一些临床研究的资料，并对未来的发展作了展望。 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-31 17:11
医学,生命科学网